CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2014—Qiagen acquired an exclusive worldwide license to the biomarker calreticulin. Qiagen licensed the technology from CeMM Vienna, the research center for molecular medicine of the Austrian Academy of Sciences. Qiagen plans to develop a molecular diagnostic test for the CALR mutations to offer patients a clearer prognostic profile and to guide disease management. The test is expected to complement the company’s kits for a key mutation of the Janus kinase 2 gene.
Qiagen, 240-686-7425